Miltefosine

CHEMBL125 Phase 4 已批准 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

407.6 g/mol

LogP

6.7

Phase

4

This oral medication disrupts the cell membranes of parasites and certain cancer cells, leading to their death. It is the first oral treatment approved for leishmaniasis, a parasitic infection transmitted by sandfly bites.

分子量

407.6000 g/mol

LogP

6.70

TPSA

58.60 Å²

Lipinski 五规则

符合

Pharmacokinetics (PK)

Pharmacodynamics (PD)

二维结构

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C

InChI

InChI=1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3

Molecular Formula

C21H46NO4P

HBD / HBA

- / 4

可旋转键数

20

重原子数

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

This oral medication disrupts the cell membranes of parasites and certain cancer cells, leading to their death. It is the first oral treatment approved for leishmaniasis, a parasitic infection transmitted by sandfly bites.

Yes, Miltefosine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL125. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3599. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

正在寻找患者友好型信息？

Miltefosine 在 PillFYI 上

结构

快速数据

分子式: C21H46NO4P
同义词: 1

外部链接

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.